Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).

Trial Details

NCT ID
NCT05703971
Phase
PHASE1 / PHASE2
Sponsor
Genprex, Inc.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • quaratusugene ozeplasmid
  • atezolizumab
Locations (sample)
  • Lone Tree, Colorado, United States|39.55171,-104.8863
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Canton, Ohio, United States|40.79895,-81.37845
  • Cincinnati, Ohio, United States|39.12711,-84.51439
  • Cincinnati, Ohio, United States|39.12711,-84.51439

Key Eligibility Criteria

  • Male or female aged ≥18 years.
  • Documented history of histologically or cytologically confirmed ES-SCLC, prior to starting treatment with the combination of atezolizumab, carbopla…
  • Complete Response (CR), Partial Response (PR), or Stable Disease (SD) after receiving at least three cycles, and no more than four cycles, of atezo…
  • Eastern Cooperative Oncology Group performance status (ECOG PS) score from 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →